Galectin Therapeutics Inc’s recent filing unveils that its Director ELDRED KARY acquired Company’s shares for reported $2611.0 on Dec 23 ’25. In the deal valued at $3.73 per share,700 shares were bought. As a result of this transaction, ELDRED KARY now holds 65,382 shares worth roughly $0.26 million.
Then, FREEMAN KEVIN D bought 5,500 shares, generating $19,514 in total proceeds. Upon buying the shares at $3.55, the Director now owns 55,269 shares.
Before that, ELDRED KARY bought 700 shares. Galectin Therapeutics Inc shares valued at $2,611 were divested by the Director at a price of $3.73 per share. As a result of the transaction, ELDRED KARY now holds 65,382 shares, worth roughly $0.26 million.
A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who remained covering the stock and in mid August has reiterated a ‘”a Buy”‘ rating for it. B. Riley FBR began covering GALT with “Buy” recommendation on February 13, 2019. H.C. Wainwright maintained its rating on December 07, 2017. It rated GALT as “a Buy”.
Price Performance Review of GALT
On Tuesday, Galectin Therapeutics Inc [NASDAQ:GALT] saw its stock fall -0.99% to $3.99. Over the last five days, the stock has lost -35.65%. Galectin Therapeutics Inc shares have risen nearly 99.50% since the year began. Nevertheless, the stocks have risen 209.30% over the past one year. While a 52-week high of $7.13 was reached on 12/17/25, a 52-week low of $0.76 was recorded on 01/14/25.
Levels Of Support And Resistance For GALT Stock
The 24-hour chart illustrates a support level at 3.64, which if violated will result in even more drops to 3.28. On the upside, there is a resistance level at 4.24. A further resistance level may holdings at 4.48.
How much short interest is there in Galectin Therapeutics Inc?
A steep rise in short interest was recorded in Galectin Therapeutics Inc stocks on 2025-11-28, dropping by 86983.0 shares to a total of 6.82 million shares. Yahoo Finance data shows the prior-month short interest on 2025-10-31 was 6.9 million shares. There was a decline of -1.28%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on November 28, 2017 when H.C. Wainwright resumed its ‘”a Buy”‘ rating for the stock and retained the price target to $6.
